利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.046 秒)

    Bicyclic compounds as modulators of androgen receptor function and method
    6.
    发明授权
    Bicyclic compounds as modulators of androgen receptor function and method 有权
    双环化合物作为雄激素受体功能和方法的调节剂

    公开(公告)号：US07388027B2

    公开(公告)日：2008-06-17

    申请号：US11070020

    申请日：2005-03-02

    申请人： James J. Li ,  Lawrence Hamann ,  David Augeri ,  Yingzhi Bi

    发明人： James J. Li ,  Lawrence Hamann ,  David Augeri ,  Yingzhi Bi

    IPC分类号： A61K31/4015 ,  C07D209/00

    CPC分类号： C07D487/04

    摘要： The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R2′ R5, G, n and W are defined herein.

    摘要翻译： 本发明涉及式I的双环化合物，含有这些化合物的药物组合物和使用这些化合物治疗雄激素受体相关病症例如年龄相关疾病，例如肌肉减少症的方法，其中R 1 R 2，R 2，R 2，R 5，G，n和W如本文所定义。

    Sulfonylpyrrolidine modulators of androgen receptor function and method
    7.
    发明申请
    Sulfonylpyrrolidine modulators of androgen receptor function and method 有权

    公开(公告)号：US20050187267A1

    公开(公告)日：2005-08-25

    申请号：US11048439

    申请日：2005-02-01

    申请人： Lawrence Hamann ,  Yingzhi Bi ,  Mark Manfredi ,  Alexandra Nirschl ,  James Sutton

    发明人： Lawrence Hamann ,  Yingzhi Bi ,  Mark Manfredi ,  Alexandra Nirschl ,  James Sutton

    IPC分类号： A61K31/4015 ,  A61K31/433 ,  C07D207/48 ,  C07D285/06 ,  C07D285/14 ,  C07D498/04

    CPC分类号： C07D285/14 ,  C07D207/48

    摘要： Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1 is hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, CO2R4a, CONR4aR4b, and CH2OR4a; R2 is hydrogen (H), OR3, SR3, halo, NHR3, NHCOR4c1, NHCO2R4c1, NHCONR4cR4d and NHSO2R4c; R3 in each functional group is hydrogen (H), alkyl or substituted alkyl, CHF2, CF3 and CON4e; R4, R4a, R4b, R4c, R4c1, R4d, R4e, R4f, R4g, or R4h in each functional group are the same or different and are hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl or substituted heteroaryl; R5 and R5′ are the same or different and are hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl or substituted heteroaryl, wherein at least one of R5 and R5′ is hydrogen, or R5 and R5′ taken together form a double bond with oxygen (O), sulfur (S), NR7 or CR7R7′; where R7 and R7′ are as defined herein; G is an aryl, heterocyclo or heteroaryl group, wherein said group is mono- or polycyclic, and which is optionally substituted; and n is an integer of 1 or 2, m is an integer of 1 or 2, Z is oxygen (—O—) or NR4h, a prodrug ester, all stereoisomers thereof and a pharmaceutically acceptable salt. A method for treating androgen receptor-associated conditions such as age-related diseases is also provided.